AdvaMed® Medical Device Mass Tort TV Ad Trend – Q4 2024

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

AdvaMed® filed an amicus brief in the case of Smith v. Terumo BCT, Inc. The case concerns whether the court should create a cause of action for asymptomatic plaintiffs, permitting recovery based solely on the possibility of future injury.

Akin will provide a CLE program covering the latest legal issues for inbound trade and investment, including the Trump Administration’s approach to trade policy and tariff issues, and strategies medical technology companies can employ to assess and mitigate legal risk. Attendees are eligible to receive 1.0 CLE.

AdvaMed®, the world’s leading medtech trade association, communicated to Centers for Medicaid & Medicare Services (CMS) recommendations regarding administration of the Open Payments program.

This case involves a patent infringement dispute between EcoFactor and Google, but the Court’s decision will reach every aspect of district court patent litigation in cases involving parties in every technological sector, including medtech. AdvaMed® highlighted the importance of Daubert’s screening and gatekeeping at the district court level.

AdvaMed®, the Medtech Association, asked the United States Court of Appeals to support a fair and balanced approach to patent damages.

The issue at hand is patent infringement and an overly broad interpretation of the Hatch-Waxman Act’s safe harbor. AdvaMed® pointed out that this would harm innovation. The decision has profound consequences for the medical technology industry, which relies on clear rules and a fair patent system to incentivize the development of life-changing technologies.